We found that binding in cis of PD1-IL2v to PD-1 and IL-2Rβγ on the cell surface of the same T cell allows IL-2v to differentiate stem-like CD8+ T cells into better effectors in the absence of CD25 binding in both chronic infection and cancer models. The gene discussed is CD8A; the disease is cancer.